Kalytera Therapeutics Inc (OTCMKTS:KALTF) Terminates LOI To Acquire Stero Biotechs, Ltd

Kalytera Therapeutics Inc (OTCMKTS:KALTF) has terminated the previously signed Letter of Intent to take over Stero Biotechs, Ltd. Chief Executive Officer and President of Kalytera said the company will explore opportunities to acquire other companies, diversify and expand its operations despite canceling the LOI to acquire Stero Biotechs.

Kalytera and former shareholders of Talent Biotechs Ltd, a subsidiary of Kalytera, have earlier agreed to extend the maturity date of the promissory note to May 15, 2020. The company expected to complete the takeover of Stero by May 15, 2020. However, Kalytera has canceled the takeover of Israel based Stero, which develops CBD for co-administration with steroids and mitigate the safety issues.

Status of annual financial statements

The securities administrators in Canada on March 18, 2020, have granted a 45-day extension for periodic filings, which are due on or before June 1, 2020, because of coronavirus crisis. According to this notice, the BC Securities Commission endorsed BC instrument 51-515, and the Alberta Securities Commission has enacted 51-517, the temporary extension from certain financial requirements. Also, the Ontario Securities Commission has endorsed Ontario Instrument 51-502, which provides a temporary extension for certain financial requirements.

Receives extension to file financial statements

As a result of these temporary extensions, Kalytera can submit the audited financial statements for the year 2019 and quarterly results for the quarter ending March 31, 2020, within 120 days and 60 days. The company also received an extension to submit the management discussion and analysis for the year 2019 and the interim period within 120 days and 60 days, respectively, as per section 5.1(2) of NI 51-102. Kalytera is in discussions with auditors and expects to complete filings on or before June 24, 2020.

Amends irrevocable selling agreement 

Kalytera amended the sale period as required by the irrevocable sale agreement between its broker and Salzman Group for its common shares. As per the amended accord, its broker will sell the shares, which are previously issued to Salzman Group, in ten trading sessions instead of five trading days. Kalytera has issued common shares (each at CAD 0.05) worth $300,000 to Salzmon Group under the payment accord for certain services.

Latest posts